Literature DB >> 7978795

Matrix metalloproteinases and their inhibitors in tumor progression.

Y A De Clerck1, H Shimada, S M Taylor, K E Langley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7978795     DOI： 10.1111/j.1749-6632.1994.tb24738.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  8 in total

1.  An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

Authors:  H Hirte; D Stewart; R Goel; E Chouinard; S Huan; S Stafford; B Waterfield; S Matthews; C Lathia; B Schwartz; V Agarwal; R Humphrey; And L Seymour
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

2.  Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study.

Authors:  Liz M Leite; Antônio Germano G Carvalho; Pollyanna L F Tavares Ferreira; Igor Xavier Pessoa; Danilo O Gonçalves; Amanda de Araújo Lopes; Jean Guilherme dos Santos Góes; Victor Costa de Castro Alves; Luzia Kalyne A M Leal; Gerly Anne Brito; Glauce S B Viana
Journal:  Inflammopharmacology       Date:  2011-02-25       Impact factor: 4.473

3.  Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix.

Authors:  S Asha Nair; D Karunagaran; M B Nair; P R Sudhakaran
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-19       Impact factor: 4.553

4.  A novel mechanism of action of tetracyclines: effects on nitric oxide synthases.

Authors:  A R Amin; M G Attur; G D Thakker; P D Patel; P R Vyas; R N Patel; I R Patel; S B Abramson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

Review 5.  Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.

Authors:  Mariza Bortolanza; Glauce C Nascimento; Sergio B Socias; Diego Ploper; Rosana N Chehín; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  J Neural Transm (Vienna)       Date:  2018-08-14       Impact factor: 3.575

6.  Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation.

Authors:  Atilla Kurt; Fatih Yanar; Oktar Asoglu; Emre Balik; Vakur Olgac; Hasan Karanlik; Sevda Tanrikulu Kucuk; Evin Ademoglu; Gulcin Yegen; Dursun Bugra
Journal:  BMC Clin Pathol       Date:  2012-12-31

7.  Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage.

Authors:  P Ring; K Johansson; M Höyhtyä; K Rubin; G Lindmark
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness?

Authors:  Manal M Zyada; Ali A Shamaa
Journal:  Diagn Pathol       Date:  2008-06-13       Impact factor: 2.644
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.